TGR BioSciences Pty Ltd (TGR) is a private biotechnology company based in Adelaide, South Australia. TGR's primary business focus is on the discovery and development of scientifically proven products that can be marketed as high-value therapies in oral and gastro-intestinal health, skin and tissue repair. A lead product is in clinical trials for the prevention of oral mucositis, the debilitating mouth ulcers that affect over 40% of all chemotherapy patients and 60% of head-neck radiotherapy patients.
TGR has a number of products in development targeted towards wound repair, tissue engineering, skin regeneration, and dermatology.
